MOUNTAIN VIEW, CA – March 21, 2023 - Adge Pharmaceuticals Inc. has begun evaluating elocalcitol, a.k.a. RO269228, a clinical stage small molecule originally developed by Roche, for the treatment of obesity and potentially other related indications with unmet medical needs.

Adge has complemented the already existing data package with relevant preclinical data supporting its use for the treatment and prevention of obesity and metabolic syndrome and is preparing to move this asset expeditiously to the clinic. The discovery of novel mechanism of action provides Adge with a powerful proprietary platform for the treatment of obesity and metabolic syndrome.

Obesity is a chronic health condition that leads to metabolic syndrome and raises the risk for heart disease and many other health problems, including type 2 diabetes and cancer. It is manifested in increase in size and amount of fat cells in the body. Nearly 50% of the US and 14% of global population are obese.

Metabolic syndrome is defined by the presence of a cluster of cardiovascular risk factors which include excess abdominal fat, hypertension, glucose intolerance, insulin resistance, high triglycerides, high LDL and low HDL.

Adge Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of best-in-class therapies for the management of obesity and metabolic syndrome.

For more information, please visit www.adgepharm.com.